JP2021513360A5 - - Google Patents

Download PDF

Info

Publication number
JP2021513360A5
JP2021513360A5 JP2020558681A JP2020558681A JP2021513360A5 JP 2021513360 A5 JP2021513360 A5 JP 2021513360A5 JP 2020558681 A JP2020558681 A JP 2020558681A JP 2020558681 A JP2020558681 A JP 2020558681A JP 2021513360 A5 JP2021513360 A5 JP 2021513360A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
amino acids
region
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020558681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513360A (ja
JP7382343B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/079949 external-priority patent/WO2019086580A1/en
Publication of JP2021513360A publication Critical patent/JP2021513360A/ja
Publication of JP2021513360A5 publication Critical patent/JP2021513360A5/ja
Application granted granted Critical
Publication of JP7382343B2 publication Critical patent/JP7382343B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020558681A 2017-11-01 2018-11-01 Mfap4に対する抗体 Active JP7382343B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17199552 2017-11-01
EP17199552.5 2017-11-01
PCT/EP2018/079949 WO2019086580A1 (en) 2017-11-01 2018-11-01 Antibodies against mfap4

Publications (3)

Publication Number Publication Date
JP2021513360A JP2021513360A (ja) 2021-05-27
JP2021513360A5 true JP2021513360A5 (enExample) 2021-12-09
JP7382343B2 JP7382343B2 (ja) 2023-11-16

Family

ID=60201899

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020558681A Active JP7382343B2 (ja) 2017-11-01 2018-11-01 Mfap4に対する抗体

Country Status (7)

Country Link
US (1) US11993649B2 (enExample)
EP (1) EP3704147A1 (enExample)
JP (1) JP7382343B2 (enExample)
CN (1) CN111315771B (enExample)
AU (1) AU2018359635B2 (enExample)
CA (1) CA3118361A1 (enExample)
WO (1) WO2019086580A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213181A1 (en) 2021-04-12 2022-10-20 Grith Lykke Sorensen Mfap4 and treatment of fibrosis
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技(成都)有限公司 针对ceacam5的抗体偶联药物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059097A1 (en) 2008-02-22 2011-03-10 University Health Network MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells
JP5872805B2 (ja) 2011-07-07 2016-03-01 花王株式会社 Mfap−4産生促進剤
CA2898239A1 (en) * 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2016008498A1 (en) 2014-07-17 2016-01-21 Syddansk Universitet Mfap4 binding antibody blocking the interaction between mfap4 and integrin receptors
CN106771201A (zh) * 2016-12-05 2017-05-31 江西惠肽生物科技有限公司 用于肝纤维化诊断试剂盒及其检测方法

Similar Documents

Publication Publication Date Title
JP2010528047A5 (enExample)
JP2018510617A5 (enExample)
JP2017535257A5 (enExample)
RU2014113046A (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP2018527919A5 (enExample)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
JP2016505546A5 (enExample)
JP2015509948A5 (enExample)
JP2018506277A5 (enExample)
JP2013502913A5 (enExample)
JP2018501197A5 (enExample)
EA033359B1 (ru) Комбинация леналидомида и полипептидной конструкции и ее применение
JP2018500014A5 (enExample)
JP2011046732A5 (enExample)
JP2016504416A5 (enExample)
JP2015503909A5 (enExample)
JP2016513664A5 (enExample)
US9932397B2 (en) VEGFA/Ang2 Compounds
RU2016145277A (ru) Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака
JP2017534645A5 (enExample)
JP2015096065A5 (enExample)
JP2018529661A5 (enExample)
WO2023151613A1 (zh) 一种双特异性抗原结合分子及其应用
IL274008B2 (en) Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment
JP2011503094A5 (enExample)